Tenpoint Therapeutics
A UK-based biotech company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases.
Tenpoint launched in July 2023 with $70 million in series A financing, which will be used to develop the company's platform which is designed to replace multiple cell types lost to inherited and age-related conditions.
Latest Tenpoint Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze